Sera Prognostics, Inc. (SERA)

NASDAQ: SERA · IEX Real-Time Price · USD
2.60
0.00 (0.00%)
Aug 12, 2022 4:00 PM EDT - Market closed
0.00%
Market Cap 80.61M
Revenue (ttm) 107,000
Net Income (ttm) -40.86M
Shares Out 31.00M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,342
Open 2.56
Previous Close 2.60
Day's Range 2.49 - 2.61
52-Week Range 1.15 - 11.90
Beta n/a
Analysts Buy
Price Target 9.69 (+272.7%)
Earnings Date Aug 29, 2022

About SERA

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The c... [Read more...]

Industry Diagnostics & Research
IPO Date Jul 15, 2021
Employees 113
Stock Exchange NASDAQ
Ticker Symbol SERA
Full Company Profile

Financial Performance

In 2021, SERA's revenue was $82,000, an increase of 228.00% compared to the previous year's $25,000. Losses were -$35.01 million, 76.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SERA stock is "Buy." The 12-month stock price forecast is 9.69, which is an increase of 272.69% from the latest price.

Price Target
$9.69
(272.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 7.50% and 22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY , Aug. 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Sera Prognostics, Inc. (SERA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10

SALT LAKE CITY, July 28, 2022 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE

SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECI...

Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY , May 19, 2022 /PRNewswire/ -- Sera Prognostics...

SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING

SALT LAKE CITY , May 18, 2022 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY , May 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...

SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUI...

Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with unanticipated preterm birth SALT LAKE CITY , May 5, 2022 /PRNewswire/ -- Sera Prognostics In...

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10

SALT LAKE CITY , May 2, 2022 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY , April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., Th...

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS

SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...

Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Fact...

SALT LAKE CITY , March 18, 2022 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on Ma...

SALT LAKE CITY , March 18, 2022 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

SALT LAKE CITY, March 3, 2022 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE

SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES

SALT LAKE CITY, Feb. 7, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker i...

SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST

SALT LAKE CITY, Feb. 1, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker i...

SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX

SALT LAKE CITY, Dec. 15, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...

Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm ...

SALT LAKE CITY, Dec 2, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker in...

Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-...

SALT LAKE CITY, Dec. 1, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker i...

Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board

SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...

Sera Prognostics Reports Third Quarter 2021 Financial Results

SALT LAKE CITY, Nov. 9, 2021 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...

Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board

SALT LAKE CITY, Nov. 8, 2021 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs

SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...